Novo Nordisk A/S (NVO) Outperformed and Reported 16% Sales Growth in Q4

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, its Investor Class fund ARTRX returned 5.84%, Advisor Class fund APDRX posted a return of 5.90%, and Institutional Class fund APHRX returned 5.94%, compared to a return of 9.76 % for the MSCI All Country World Index. In addition, please check the fund’s top five holdings to know its best picks in 2022.

Artisan Global Opportunities Fund highlighted stocks like Novo Nordisk A/S (NYSE:NVO) in the Q4 2022 investor letter. Headquartered in Bagsvaerd, Denmark, Novo Nordisk A/S (NYSE:NVO) is a healthcare company. On March 10, 2023, Novo Nordisk A/S (NYSE:NVO) stock closed at $141.29 per share. One-month return of Novo Nordisk A/S (NYSE:NVO) was -1.19%, and its shares gained 38.87% of their value over the last 52 weeks. Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $322.203 billion.

Artisan Global Opportunities Fund made the following comment about Novo Nordisk A/S (NYSE:NVO) in its Q4 2022 investor letter:

“Novo Nordisk A/S (NYSE:NVO) is the global leader in insulin production and diabetes treatment. We believe the company’s drugs for treating diabetes— decreasing blood sugar and weight—have a solid profit cycle runway ahead. However, our core investment thesis is centered around the company’s opportunity in the obesity market with its Wegovy® offering, which is an injectable prescription medication serving as a potentially safer alternative to bariatric surgery. Wegovy® is commercially approved and has the potential to capture meaningful share of what we expect will be a massive market opportunity considering both the total addressable market combined and the recurring revenue of the medication that must be taken chronically to maintain effectiveness. For the quarter, the company reported 16% growth in sales, but sales within its obesity segment grew by 75%.”

Robyn Mackenzie/Shutterstock.com

Novo Nordisk A/S (NYSE:NVO) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held Novo Nordisk A/S (NYSE:NVO) at the end of the fourth quarter which was 40 in the previous quarter.

We discussed Novo Nordisk A/S (NYSE:NVO) in another article and shared ClearBridge Sustainability Leaders Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

• 11 Best Debt Free Stocks to Buy
• 10 Penny Stocks with Insider Buying
• 15 Biggest Poultry Companies in the World

Disclosure: None. This article is originally published at Insider Monkey.